Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Winter;37(1):25-32.
doi: 10.11607/ofph.3163.

Novel Migraine Treatments: A Review

Naveen George, Stewart J Tepper
Review

Novel Migraine Treatments: A Review

Naveen George et al. J Oral Facial Pain Headache. 2023 Winter.

Abstract

Aims: To present a review of the mechanisms of action, available clinical data, and safety profiles of novel migraine therapeutics to inform practice. Methods: PubMed, Medline, and Google Scholar were searched for randomized controlled trials (24 publications), review articles (15 publications), and other pertinent literature (16 publications) discussing the novel migraine therapeutics available between the years 2010 and 2021. All publications were reviewed to assess the mechanism of action, relevant clinical data, and side effect profile for each novel treatment. Therapeutic gain was also recorded in studies that included a placebo arm. Results: A total of 55 studies were included in the final analysis. In the preventive treatment of migraine, novel medications target calcitonin gene-related peptide (CGRP) and fall into either the monoclonal anti-CGRP or gepant class. For the acute treatment of migraine, novel medications fall into either the ditan or gepant class. Several medical devices have been developed for the acute and preventive treatment of migraine. Conclusion: Novel therapeutics are available for both the prevention and acute treatment of migraine headaches. These new medications and neuromodulatory devices appear overall to be safe and effective in the management of migraine headaches.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Headache Classification Committee of the International Headache Society (IHS) The international classification of headache disorders. Cephalalgia. (3rd edition) 2018;38:1–211. - PubMed
    1. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4:386–398. - PubMed
    1. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999;159:813–818. - PubMed
    1. Ruthirago D, Julayanont P, Kim J. Translational correlation: Migraine. In: Michael Conn P, editor. Conn’s Translational Neuroscience. London: Academic Press; 2017. pp. 159–165.
    1. de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;105:815–825. - PubMed

MeSH terms

Substances